Trial Profile
A double-blind, placebo-controlled, randomized, multicenter study to investigate the safety and efficacy of 2 mg TID of cilansetron over 12 weeks followed by a 4-week rerandomization treatment period in diarrhea predominate irritable bowel syndrome subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Nov 2006
Price :
$35
*
At a glance
- Drugs Cilansetron (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Solvay Pharmaceuticals
- 13 Nov 2006 New trial record.